-
Mashup Score: 7
Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Dr Patel on Findings From the TRUST-II Trial in ROS1+ NSCLC - 29 day(s) ago
Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Lurie Cancer Center’s @JPatelMD on Findings From the TRUST-II Trial in ROS1+ #NSCLC https://t.co/qkZ4NckpCq via @onclive #lcsm
-
-
Mashup Score: 13Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC - 1 month(s) ago
The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. https://t.co/KaFvs9VsEI #LCSM @max_diehn https://t.co/V4nhQtbH9Y
-
-
Mashup Score: 26
PURPOSEPreclinical studies demonstrated that dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways delay the emergence of resistance to EGFR tyrosine kinase inhibitors (TKIs), and in trials with …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Randomized Phase 2 RAMOSE Study of Osimertinib With & Without Ramucirumab in Tyrosine Kinase Inhibitor–Naive EGFR-Mutant Metastatic #NSCLC: https://t.co/7Nc69Durip #lcsm @LeXiuning @MDAndersonNews @JPatelMD @ElaineShumMD @CatherineShuMD @chulkimMD @maryjofidlerMD
-
-
Mashup Score: 13Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC - 1 month(s) ago
The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. https://t.co/KaFvs9VsEI #LCSM @max_diehn https://t.co/V4nhQtbH9Y
-
-
Mashup Score: 1
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung cancer setting in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Ticiana Leal, MD, (@LealTiciana) discusses phase 3 trials of combinations in the #NSCLC setting in the second article of a 2-part series. #lcsm https://t.co/hy8ujl3aDd
-
-
Mashup Score: 4
Definitive radiation therapy is considered standard therapy for medically inoperable early-stage NSCLC. Nevertheless, for patients with tumors located near structures such as the proximal tracheobronchial tree, esophagus, heart, spinal cord, and brachial plexus, the optimal management regimen is controversial. The objective was to develop expert multidisciplinary consensus guidelines on managing medically inoperable NSCLC located in a central or ultracentral location relative to critical organs at risk.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
The ARS Thoracic AUC panel has developed expert multidisciplinary consensus guidelines on managing medically inoperable #NSCLC located in a central or ultracentral location relative to critical organs at risk. https://t.co/j2VtU86jwI #LCSM @HenryParkMD @YaleRadOnc https://t.co/CMoEGGeK2O
-
-
Mashup Score: 13Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC - 1 month(s) ago
The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. https://t.co/KaFvs9VsEI #LCSM @max_diehn https://t.co/V4nhQtbH9Y
-
-
Mashup Score: 4Adagrasib Demonstrates Superiority in KRAS G12C NSCLC - 1 month(s) ago
Robert Jotte, MD, PhD, discusses findings from the phase 3 KRYSTAL-12 study evaluating adagrasib in KRAS G12C-mutated NSCLC.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Robert Jotte, MD, PhD, discusses findings from the phase 3 KRYSTAL-12 study evaluating adagrasib in KRAS G12C-mutated #NSCLC. #lcsm https://t.co/FIBhckXjle
-
-
Mashup Score: 0
Two radiation therapy techniques, SBRT and hypofractionated CRT, may not have many differences for patients with stage 1 NSCLC, but limitations matter.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
In patients with stage 1 #NSCLC, two types of radiation therapy, SBRT or hypofractionated CRT, may not have many differences. However, limitations from the respective study matter, @BismarckOdeiMD of @UofURadOnc @huntsmancancer told CURE®. #LCSM https://t.co/y6zW8nEvTp
-
Ivonescimab Reduces Risk of Progression Over Pembrolizumab in PD-L1+ Advanced #NSCLC | #lcsm @MDAndersonNews https://t.co/9gIGDBZNS6